Stuart Isaacson

Stuart Isaacson

UNVERIFIED PROFILE

Are you Stuart Isaacson?   Register this Author

Register author
Stuart Isaacson

Stuart Isaacson

Publications by authors named "Stuart Isaacson"

Are you Stuart Isaacson?   Register this Author

43Publications

1532Reads

42Profile Views

Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin.

Expert Rev Clin Pharmacol 2019 Jul 13;12(7):681-691. Epub 2019 Jun 13.

e Parkinson's Disease and Movement Disorders Center of Boca Raton , Boca Raton , FL , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17512433.2019.1623669DOI Listing
July 2019

Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials.

Parkinsonism Relat Disord 2019 Mar 5;60:118-125. Epub 2018 Sep 5.

Adamas Pharmaceuticals, Inc., 1900 Powell Street Suite 750, Emeryville, CA, 94608, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.09.005DOI Listing
March 2019

Role of the Personal KinetiGraph in the routine clinical assessment of Parkinson's disease: recommendations from an expert panel.

Expert Rev Neurother 2018 08 26;18(8):669-680. Epub 2018 Jul 26.

f Florey Neuroscience Institute , University of Melbourne , Parkville , Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1503948DOI Listing
August 2018

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.

Int J Neurosci 2018 Jul 17;128(7):619-626. Epub 2018 Jan 17.

h Methodist Neurological Institute , Houston , TX , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00207454.2017.1406935DOI Listing
July 2018

Clinical utility of DaTscan™ imaging in the evaluation of patients with parkinsonism: a US perspective.

Expert Rev Neurother 2017 03 23;17(3):219-225. Epub 2016 Nov 23.

g Institute for Neurodegenerative Disorders , New Haven , CT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2017.1256205DOI Listing
March 2017

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension.

Clin Neuropharmacol 2016 Sep-Oct;39(5):220-6

*Parkinson's Disease and Movement Disorders Center, University of South Florida Health, Byrd Institute, Tampa, FL; †Monash University, Melbourne, Australia; ‡Lundbeck, Deerfield, IL; and §Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028156PMC
http://dx.doi.org/10.1097/WNF.0000000000000168DOI Listing
January 2017

Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.

J Am Soc Hypertens 2016 10 4;10(10):755-762. Epub 2016 Aug 4.

Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington, CT 06032, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jash.2016.07.010DOI Listing
October 2016

Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.

Mov Disord 2016 09 19;31(9):1366-72. Epub 2016 Jul 19.

Cynapsus Therapeutics, Inc, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26697DOI Listing
September 2016

Apomorphine Subcutaneous Injection for the Management of Morning Akinesia in Parkinson's Disease.

Mov Disord Clin Pract 2017 Jan-Feb;4(1):78-83. Epub 2016 May 25.

Georgetown University Medical Center Washington DC USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298032PMC
May 2016

Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis.

J Am Med Dir Assoc 2015 Oct 1;16(10):898.e1-7. Epub 2015 Aug 1.

Institute of Neuroscience, Newcastle University, Newcastle, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamda.2015.06.021DOI Listing
October 2015

Managed care approach to the treatment of neurogenic orthostatic hypotension.

Am J Manag Care 2015 Oct;21(13 Suppl):s258-68

View Article

Download full-text PDF

Source
October 2015

Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).

Mov Disord 2015 Apr 9;30(5):646-54. Epub 2014 Dec 9.

University of South Florida, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.26086DOI Listing
April 2015

Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).

J Parkinsons Dis 2014 ;4(1):57-65

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JPD-130259DOI Listing
October 2014

Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.

Vasc Health Risk Manag 2014 3;10:169-76. Epub 2014 Apr 3.

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/VHRM.S53983DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3979788PMC
September 2014

Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.

Mov Disord 2014 Jul 11;29(8):1028-34. Epub 2014 Jun 11.

Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.25877DOI Listing
July 2014

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.

Lancet 2014 Feb 1;383(9916):533-40. Epub 2013 Nov 1.

Wolfson Centre for Age-Related Diseases, King's College, London, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(13)62106-6DOI Listing
February 2014

Tolerability and efficacy of switching from oral selegiline to Zydis selegiline in patients with Parkinson's disease.

Parkinsonism Relat Disord 2011 Feb 16;17(2):117-8. Epub 2010 Nov 16.

Dept. of Neurology, Baylor college of Medicine, 6550 Fannin, Ste 1801, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2010.10.001DOI Listing
February 2011

Increased melanoma risk in Parkinson disease: a prospective clinicopathological study.

Arch Neurol 2010 Mar;67(3):347-52

Department of Neurological Sciences, University of Nebraska Medical Center, 982045 Nebraska Medical Center, Omaha, NE 68198-2045, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneurol.2010.1DOI Listing
March 2010

Selective MAO-B inhibitors have low potential for the tyramine effect.

Mov Disord 2010 Jan;25(1):123-4

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.22334DOI Listing
January 2010

Improving symptom control in early Parkinson's disease.

Ther Adv Neurol Disord 2009 Nov;2(6):29-41

Voluntary Assistant Professor of Neurology, University of Miami School of Medicine, Miami, FL; Director, Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756285609339383DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002604PMC
November 2009

Levodopa/carbidopa/entacapone 200/50/200 mg (Stalevo 200) in the treatment of Parkinson's disease: a case series.

Cases J 2009 Jul 30;2:7134. Epub 2009 Jul 30.

Movement Disorders Program, Medical College of Georgia, Augusta, Georgia 30912, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4076/1757-1626-2-7134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740140PMC
July 2009